We are excited to share that Dr. Darius-Jean Namdjou, our Director, Senior Regulatory Lead at Phortas, recently participated in the...

We are thrilled to share that Jasmina Savic, our Managing Director at Phortas, recently participated in the European Medicines Agency...

Phortas has joined EU-X-CT: An initiative that seeks to enable and facilitate cross-border access to clinical trials for patients in...

Three years ago The FDA and the European Medicines Agency (EMA) have initiated a pilot program aimed at offering parallel scientific...

We are delighted to announce that our two senior Phortas members will be presenting at RAPS Euro Convergence, scheduled from 06-08 May...

At Phortas, we are excited to share some remarkable news with you - we will be attending BioSpain 2023, one of Europe's premier...

Prior to initiating a drug development program there are certain questions and considerations that should be answered with the main aim...

Intro The pharmaceutical industry has experienced significant growth during the past two decades, and pharma revenues worldwide totalled...

The definition of rare disease varies across countries and jurisdictions, but it usually takes into account disease prevalence, severity...

What became evident with the introduction of the Paediatric Investigation Plan (PIP) procedure in Europe is that Regulatory Experts need...